Company Overview of Novartis Oncology
Novartis Oncology engages in the discovery and development of therapies and medicines for cancer. It focuses on the research platforms spanning discoveries in signal transduction inhibition, cytotoxic agents, antiangiogenesis, cell cyle/apoptosis, iron chelation, metastases, and hormone therapy. The company’s products include EXJADE, a drug indicated for the treatment of chronic iron overload due to frequent blood transfusions; Femara letrozole tablets indicated for the treatment of breast cancer in postmenopausal women; Glivec, a cancer treatment indicated for adult and pediatric patients with diagnosed Ph+ chronic myeloid leukemia; and Sandostatin LAR octreotide/IM injection for the treatm...
One Health Plaza
East Hanover, NJ 07936 1080
Key Executives for Novartis Oncology
Global Head of Oncology Development and Executive Vice President
Vice President and Global Head of NIBR Oncology Research
Compensation as of Fiscal Year 2015.
Novartis Oncology Key Developments
Novartis Oncology Announces Sales Results for the First Half of 2015
Jul 21 15
Novartis Oncology announced sales results for the first half of 2015. For the period, sales grew 30%.
Novartis Oncology Presents at BIO-Europe 2014, Nov-03-2014 02:45 PM
Oct 31 14
Novartis Oncology Presents at BIO-Europe 2014, Nov-03-2014 02:45 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Anne Altmeyer, VP, Business Development and Licensing.
Novartis Oncology Announces Executive Changes
Jun 1 14
Novartis AG said that it has appointed a senior executive of Merck & Co. (MRK), Bruno Strigini, as president of its oncology business, Novartis Oncology. His appointment is with immediate effect. Novartis said in mid-January that Herve Hoppenot resigned as president of Novartis Oncology to pursue a career opportunity outside of the organization. At that time, the company appointed Alessandro Riva as president of Novartis Oncology on an interim basis, until a successor was found for Hoppenot who has led the oncology business since 2010. Strigini most recently served as president for Merck's Europe/Canada operations. He has 25 years of experience in pharmaceuticals, animal health, OTC and vaccines, having led in both international and local roles. Strigini is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations or EFPIA, as well as a member of the Academie Nationale de Pharmacie in France.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries